🚀 Welcome to the Team, Rob Jenkins! 🔬
February 24, 2025
Pharmidex is thrilled to welcome
Rob Jenkins as our new Principal Scientist! 🎉
We are extremely happy and grateful to have Rob join our team, bringing his expertise and passion for bioanalysis to our mission of advancing drug discovery and development.
His skills and dedication will be invaluable as we continue to deliver high-quality scientific solutions to our partners and clients.
Join us in giving Robert a warm welcome, we're excited for the journey ahead!
#Welcome #Pharmidex #Bioanalysis #DrugDiscovery #TeamGrowth
We’re delighted to announce that Pharmidex will be an official sponsor of CamMedChem’25 , the renowned meeting organized by the Royal Society of Chemistry’s Biomolecular Chemistry Special Interest Group This year’s theme promises cutting-edge discussions in medicinal chemistry, biomolecular interactions and the latest trends in small molecule and chemical biology research. We’re honoured to support such a pivotal forum for scientists, drug discovery experts and academic innovators to exchange ideas, foster collaborations, and advance therapeutic discovery. 👉 We look forward to: Learning from the powerful scientific insights shared at the meeting Exploring new partnerships that further the translation of biomolecular science into impactful therapies We can’t wait to see you in Cambridge for CamMedChem’25!
At Pharmidex , we deliver comprehensive histology solutions designed to support preclinical and clinical research with accuracy and reliability. 🔬 From sample to slide, our services include: tissue processing, embedding, microtomy, routine and special staining, digital imaging and slide scanning all underpinned by rigorous quality control and expert scientific oversight. With specialist capabilities and high-throughput workflows, we help researchers generate high-quality, reproducible data across toxicology, oncology, CNS and beyond. 👉 Learn more: pharmidex.com/histology
At Pharmidex , we are proud to offer a comprehensive preclinical platform for autoimmune disease research. Using in vivo EAE models, we combine: ✔️ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression ✔️ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs ✔️ Pharmacological intervention studies, including established treatments such as Fingolimod for validation This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation. By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects. 👉 Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.
